Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Rosiglitazone

Study type: Observational

Funder types: Industry

Identifiers

NCT00995995

113030

Details and patient eligibility

About

Carry out the cost-effectiveness analysis of rosiglitazone on a population in line with the rosiglitazone license and using UK costs

Enrollment: 7,641 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Rosiglitazone Type II Diabetes studies

Exclusion criteria

• Studies without the required outcome

Trial design

7,641 participants in 1 patient group

All patients

Treatment:

Drug: Rosiglitazone